Integra LifeSciences Holdings Co. (NASDAQ:IART) Receives $27.25 Average PT from Brokerages

Integra LifeSciences Holdings Co. (NASDAQ:IART) has received an average recommendation of “Reduce” from the eight analysts that are covering the stock, MarketBeat reports. Three analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and one has given a buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $24.00.

Several analysts have issued reports on IART shares. Truist Financial dropped their price target on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a research report on Monday, October 14th. BTIG Research upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating in a report on Monday, October 7th. Bank of America dropped their price objective on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating on the stock in a research note on Monday, October 7th. Citigroup lifted their target price on Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a research note on Tuesday, November 5th. Finally, JMP Securities decreased their target price on Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating on the stock in a report on Tuesday, July 30th.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Capital Research Global Investors lifted its stake in shares of Integra LifeSciences by 37.7% in the 1st quarter. Capital Research Global Investors now owns 5,918,981 shares of the life sciences company’s stock valued at $209,828,000 after acquiring an additional 1,621,655 shares during the last quarter. Jane Street Group LLC boosted its stake in shares of Integra LifeSciences by 181.1% during the first quarter. Jane Street Group LLC now owns 124,887 shares of the life sciences company’s stock valued at $4,427,000 after purchasing an additional 80,463 shares in the last quarter. SG Americas Securities LLC grew its holdings in shares of Integra LifeSciences by 606.9% during the second quarter. SG Americas Securities LLC now owns 67,471 shares of the life sciences company’s stock worth $1,966,000 after purchasing an additional 57,927 shares during the last quarter. Boston Partners acquired a new position in shares of Integra LifeSciences in the first quarter valued at approximately $19,383,000. Finally, Point72 Europe London LLP raised its holdings in Integra LifeSciences by 13.8% in the 2nd quarter. Point72 Europe London LLP now owns 546,035 shares of the life sciences company’s stock valued at $15,911,000 after buying an additional 66,400 shares during the last quarter. Institutional investors and hedge funds own 84.78% of the company’s stock.

Integra LifeSciences Stock Performance

Integra LifeSciences stock opened at $23.27 on Tuesday. Integra LifeSciences has a 1 year low of $16.81 and a 1 year high of $45.42. The company’s 50-day moving average is $19.46 and its two-hundred day moving average is $24.25. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. The company has a market cap of $1.80 billion, a PE ratio of -258.53, a PEG ratio of 0.84 and a beta of 1.08.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.02. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The business had revenue of $380.80 million for the quarter, compared to the consensus estimate of $375.81 million. During the same period last year, the company posted $0.76 EPS. Integra LifeSciences’s revenue for the quarter was down .4% on a year-over-year basis. Equities analysts anticipate that Integra LifeSciences will post 2.45 earnings per share for the current year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.